Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Alaunos Therapeutics (TCRT) Non Operating Income (2016 - 2025)

Alaunos Therapeutics (TCRT) has disclosed Non Operating Income for 15 consecutive years, with $28000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non Operating Income rose 21.74% year-over-year to $28000.0, compared with a TTM value of $79000.0 through Sep 2025, down 92.68%, and an annual FY2024 reading of $133000.0, down 87.31% over the prior year.
  • Non Operating Income was $28000.0 for Q3 2025 at Alaunos Therapeutics, up from $19000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $959000.0 in Q4 2023 and bottomed at -$703000.0 in Q1 2022.
  • Average Non Operating Income over 5 years is $56631.6, with a median of $23000.0 recorded in 2024.
  • Peak annual rise in Non Operating Income hit 12400.0% in 2022, while the deepest fall reached 7911.11% in 2022.
  • Year by year, Non Operating Income stood at $2000.0 in 2021, then skyrocketed by 12400.0% to $250000.0 in 2022, then soared by 283.6% to $959000.0 in 2023, then tumbled by 98.64% to $13000.0 in 2024, then surged by 115.38% to $28000.0 in 2025.
  • Business Quant data shows Non Operating Income for TCRT at $28000.0 in Q3 2025, $19000.0 in Q2 2025, and $19000.0 in Q1 2025.